X4 Pharmaceuticals collects $37.5 mln Series A

Cambridge, Massachusetts-based X4 Pharmaceuticals, a developer of treatments focused on improving immune cell trafficking and increasing the ability for T-Cells to track and destroy cancer cells, has secured $37.5 million in Series A funding. Cormorant Asset Management led the round. Maxim Merchant Capital was the placement agent.

North AmericaUSBriefs